AXIM (AXIM Biotechnologies) Accounts Payable & Accrued Expense: $1.85 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is AXIM Biotechnologies Accounts Payable & Accrued Expense?

AXIM Biotechnologies AXIM +18.18% Accounts Payable & Accrued Expense is $1.85 Mil as of Jun. 2025.

AXIM Biotechnologies's quarterly accounts payable & accrued expense increased from Dec. 2024 ($1.84 Mil) to Mar. 2025 ($1.98 Mil) but then declined from Mar. 2025 ($1.98 Mil) to Jun. 2025 ($1.85 Mil).

AXIM Biotechnologies's annual accounts payable & accrued expense increased from Dec. 2022 ($1.34 Mil) to Dec. 2023 ($2.80 Mil) but then declined from Dec. 2023 ($2.80 Mil) to Dec. 2024 ($1.84 Mil).

AXIM Biotechnologies Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Accounts Payable & Accrued Expense Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 0.94 1.34 2.80 1.84

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.64 1.69 1.84 1.98 1.85

AXIM Biotechnologies Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $1.85 Mil mean?
AXIM Biotechnologies (AXIM) has a Accounts Payable & Accrued Expense of $1.85 Mil as of Jun. 2025. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Accounts Payable & Accrued Expense too high?
AXIM Biotechnologies' current Accounts Payable & Accrued Expense is $1.85 Mil.
How does AXIM Biotechnologies' Accounts Payable & Accrued Expense compare to ZVSA and HEPA?
AXIM Biotechnologies' Accounts Payable & Accrued Expense of $1.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Accounts Payable & Accrued Expense is $1.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Accounts Payable & Accrued Expense of $1.85 Mil. The current Accounts Payable & Accrued Expense is $1.85 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Accounts Payable & Accrued Expense is $1.85 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.